Luo Minqi, Liu Huan, Zhuang Ke, Liu Li, Su Bo, Yang Rongrong, Tien Po, Zhang Linqi, Gui Xien, Chen Zhiwei
Modern Virology Research Center and AIDS Center, State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Hubei 430072, P.R. China.
†Zhongnan Hospital, Wuhan University, Wuhan 430071, China.
J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):1-8. doi: 10.1097/QAI.0b013e31818ffcdc.
To determine the prevalence of drug-resistant HIV-1 and the efficacy of first-line highly active antiretroviral therapy (HAART) regimens consisted of generic nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor among 339 study subjects in rural areas of Hubei province, China.
Two cross-sectional studies were conducted to investigate 150 HAART-naive (99 received subsequent therapy) between 2003 and 2005 and 288 HAART-experienced patients mainly between 2005 and 2006. Patients' CD4+ T-cell count and viral load were determined. HIV-1 pol gene fragments were amplified from patients' plasma by reverse transcriptase-polymerase chain reaction, subsequently sequenced and analyzed.
About 83.5% of the patients were from rural villages. They were dominantly infected with subtype B' HIV-1 (96.7%) through paid blood donation (64.6%) and related blood transfusion (28.3%). We found that there was a steady increase of CD4 count over time among treated patients without detectable viral load (186/288, 64.6%). There was, however, an increasing prevalence of nucleoside reverse transcriptase inhibitor- and nonnucleoside reverse transcriptase inhibitor-resistant mutations among patients with detected viremia (102/288, 35.4%) after treatment for 3-6 (24.3%), 9-12 (57.1%), and 20-24 (63.3%) months, respectively. The increasing rates were associated with significant CD4 count drop and viral load increase. Some patients also developed multidrug-resistant mutants.
: We report the first HIV-1 drug resistance study after 2 years on HAART among Chinese patients living in rural villages. Our data suggest that a significant portion of patients are failing first-line regimens with a trend of AIDS progression. It is therefore necessary to maximize the drug adherence and to make affordable second-line HAART regimens available immediately. Our results have implications for implementing HAART in underresourced developing country settings.
在中国湖北省农村地区的339名研究对象中,确定耐多药HIV-1的流行情况以及由通用核苷类逆转录酶抑制剂和非核苷类逆转录酶抑制剂组成的一线高效抗逆转录病毒治疗(HAART)方案的疗效。
进行了两项横断面研究,分别在2003年至2005年期间调查了150例初治HAART患者(99例随后接受了治疗),以及主要在2005年至2006年期间调查了288例接受过HAART治疗的患者。测定患者的CD4+T细胞计数和病毒载量。通过逆转录-聚合酶链反应从患者血浆中扩增HIV-1 pol基因片段,随后进行测序和分析。
约83.5%的患者来自农村。他们主要通过有偿献血(64.6%)和相关输血(28.3%)感染B'亚型HIV-1(96.7%)。我们发现,在病毒载量不可检测的接受治疗患者中(186/288,64.6%),CD4计数随时间稳步增加。然而,在治疗3至6个月(24.3%)、9至12个月(57.1%)和20至24个月(63.3%)后,病毒血症患者中核苷类逆转录酶抑制剂和非核苷类逆转录酶抑制剂耐药突变的患病率呈上升趋势(10